2022 Fiscal Year Research-status Report
Creation of a lymphatic drug delivery system: controlling distant metastasis and immune-related adverse events
| Project/Area Number |
22K18203
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Keywords | リンパ節 / 治療 / 転移 / DDS |
|---|
| Outline of Annual Research Achievements |
This fiscal year, we aim to investigate immune check inhibitor (ICI) against lymph node metastasis and onset development of irAE during treatment, we worked on the following issues.
(1) Evaluation of treatment outcome of immune check point inhibitor (ICI) for local control and prevention of lung metastasis via lymphatic drug delivery system (LDDS). MXH10/Mo/lpr mice were inoculated with tumor cells into the subiliac lymph node (SiLN), and CTLA4 was injected into tumor-inoculated SiLN on day 4 and 8 after inoculation. 10 mg/kg CTLA4 was able to inhibit tumor growth in the SiLN for one-side inoculation group, whereas SiLN and lung in both-side inoculation group with reduced irAEs such as sialadenitis and pneumonia.
(2) To improve treatment outcome with reduced irAE, we are using anticancer drug with ICI through the LDDS. MXH10/Mo/lpr mice were inoculated with tumor cells into the SiLN, and chemoimmunotherapy is performed with combination of Doxorubicin and CTLA4 into tumor-inoculated SiLN on different sequences and days to optimize perfect combination.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
As per the application form for issuance.
|
| Strategy for Future Research Activity |
(1) Evaluation of treatment outcome of immune check point inhibitor (ICI) for local control and prevention of lung metastasis via lymphatic drug delivery system (LDDS).
We will continue the experiment for activation of lung metastasis after lymphadenopathy.
(2) To improve treatment outcome with reduced irAE, we are using anticancer drug with ICI through the LDDS.
We will conduct an experiment on chemoimmunotherapy with combination of Doxorubicin and CTLA4 via LDDS.
|
| Causes of Carryover |
The unused amount generated by the efficient promotion of research in the current fiscal year will be used in the next fiscal year (FY). This amount, together with the amount requested for FY2023, will be used to carry out research in FY2023.
|
